

Aaron Tan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1096950/publications.pdf>

Version: 2024-02-01

49
papers

2,536
citations

430874

18
h-index

243625

44
g-index

49
all docs

49
docs citations

49
times ranked

3024
citing authors

#	ARTICLE	IF	CITATIONS
1	Management of glioblastoma: State of the art and future directions. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 299-312.	329.8	969
2	Targeting the PI3K/Akt/mTOR pathway in non-small cell lung cancer (NSCLC). <i>Thoracic Cancer</i> , 2020, 11, 511-518.	1.9	275
3	Targeted Therapies for Lung Cancer Patients With Oncogenic Driver Molecular Alterations. <i>Journal of Clinical Oncology</i> , 2022, 40, 611-625.	1.6	242
4	FDG-PET response and outcome from anti-PD-1 therapy in metastatic melanoma. <i>Annals of Oncology</i> , 2018, 29, 2115-2120.	1.2	131
5	Molecular Pathways for Cancer Chemoprevention by Dietary Phytochemicals. <i>Nutrition and Cancer</i> , 2011, 63, 495-505.	2.0	129
6	Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis. <i>Lung Cancer</i> , 2020, 139, 207-215.	2.0	79
7	Adapting to a Pandemic – Conducting Oncology Trials during the SARS-CoV-2 Pandemic. <i>Clinical Cancer Research</i> , 2020, 26, 3100-3103.	7.0	53
8	Intratumoral CD39+CD8+ T Cells Predict Response to Programmed Cell Death Protein-1 or Programmed Death Ligand-1 Blockade in Patients With NSCLC. <i>Journal of Thoracic Oncology</i> , 2021, 16, 1349-1358.	1.1	48
9	The Paradoxical Effects of COVID-19 on Cancer Care: Current Context and Potential Lasting Impacts. <i>Clinical Cancer Research</i> , 2020, 26, 5809-5813.	7.0	44
10	Systematic review of combinations of targeted or immunotherapy in advanced solid tumors. , 2021, 9, e002459.		41
11	Potential Antioxidant, Antiinflammatory, and Proapoptotic Anticancer Activities of Kakadu Plum and Illawarra Plum Polyphenolic Fractions. <i>Nutrition and Cancer</i> , 2011, 63, 1074-1084.	2.0	38
12	Native Australian Fruit Polyphenols Inhibit Cell Viability and Induce Apoptosis in Human Cancer Cell Lines. <i>Nutrition and Cancer</i> , 2011, 63, 444-455.	2.0	37
13	Antioxidant and cytoprotective activities of native Australian fruit polyphenols. <i>Food Research International</i> , 2011, 44, 2034-2040.	6.2	32
14	Chemotherapy-induced peripheral neuropathy – patient-reported outcomes compared with NCI-CTCAE grade. <i>Supportive Care in Cancer</i> , 2019, 27, 4771-4777.	2.2	30
15	Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC. <i>Journal of Thoracic Oncology</i> , 2020, 15, 1928-1934.	1.1	30
16	Native Australian fruit polyphenols inhibit COX-2 and iNOS expression in LPS-activated murine macrophages. <i>Food Research International</i> , 2011, 44, 2362-2367.	6.2	27
17	Immune Checkpoint Inhibitors in Gliomas. <i>Current Oncology Reports</i> , 2017, 19, 23.	4.0	27
18	High-Throughput Screening Platform for Anticancer Therapeutic Drug Cytotoxicity. <i>Assay and Drug Development Technologies</i> , 2008, 6, 711-722.	1.2	25

#	ARTICLE	IF	CITATIONS
19	Association of Clinicopathologic and Molecular Tumor Features With Recurrence in Resected Early-Stage Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer. <i>JAMA Network Open</i> , 2021, 4, e2131892.	5.9	25
20	Brain Metastases in Lung Cancers with Emerging Targetable Fusion Drivers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1416.	4.1	21
21	Integrative Profiling of T790M-Negative EGFR-Mutated NSCLC Reveals Pervasive Lineage Transition and Therapeutic Opportunities. <i>Clinical Cancer Research</i> , 2021, 27, 5939-5950.	7.0	21
22	New drug developments in metastatic gastric cancer. <i>Therapeutic Advances in Gastroenterology</i> , 2018, 11, 175628481880807.	3.2	19
23	Immune Checkpoint Inhibitors for Brain Metastases. <i>Current Oncology Reports</i> , 2017, 19, 38.	4.0	18
24	Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. <i>Clinical Cancer Research</i> , 2022, 28, 585-593.	7.0	18
25	Deficiency of the splicing factor RBM10 limits EGFR inhibitor response in EGFR-mutant lung cancer. <i>Journal of Clinical Investigation</i> , 2022, 132, .	8.2	15
26	Salting the Soil: Targeting the Microenvironment of Brain Metastases. <i>Molecular Cancer Therapeutics</i> , 2021, 20, 455-466.	4.1	13
27	Bystander CD4 ⁺ T cells infiltrate human tumors and are phenotypically distinct. <i>Oncotarget</i> , 2022, 11, .	4.6	13
28	Characteristics and outcomes of oncology unit patients requiring admission to an Australian intensive care unit. <i>Internal Medicine Journal</i> , 2019, 49, 734-739.	0.8	11
29	Complementary and alternative medicine in diabetes (CALMIND) – a prospective study. <i>Journal of Complementary and Integrative Medicine</i> , 2015, 12, 95-99.	0.9	10
30	Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2018, 14, e161-e166.	1.1	10
31	Cisplatin-induced syndrome of inappropriate antidiuretic hormone secretion (SIADH) with life-threatening hyponatraemia. <i>BMJ Case Reports</i> , 2018, 2018, bcr-2017-222948.	0.5	10
32	Third generation EGFR TKI landscape for metastatic EGFR mutant non-small cell lung cancer (NSCLC). <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 431-435.	2.4	10
33	Molecular and clonal evolution in recurrent metastatic gliosarcoma. <i>Journal of Physical Education and Sports Management</i> , 2020, 6, a004671.	1.2	10
34	Clinical Characteristics and Outcomes in Advanced KRAS-Mutated NSCLC: A Multicenter Collaboration in Asia (ATORG-005). <i>JTO Clinical and Research Reports</i> , 2022, 3, 100261.	1.1	9
35	<i>Candida glabrata</i> vertebral osteomyelitis in an immunosuppressed patient. <i>International Journal of Rheumatic Diseases</i> , 2014, 17, 229-231.	1.9	8
36	Utility of 1-year FDG-PET (PET) to determine outcomes from anti-PD-1 (PD1) based therapy in patients (pts) with metastatic melanoma (MM).. <i>Journal of Clinical Oncology</i> , 2018, 36, 9517-9517.	1.6	8

#	ARTICLE	IF	CITATIONS
37	Clinical Trial Eligibility Criteria and Recently Approved Cancer Therapies for Patients With Brain Metastases. <i>Frontiers in Oncology</i> , 2021, 11, 780379.	2.8	7
38	An ethnopharmacological approach to the preliminary screening of native Australian herbal medicines for anticancer activity. <i>Journal of Complementary and Integrative Medicine</i> , 2015, 12, 245-9.	0.9	4
39	Individualized Molecular Profiling for Allocation to Clinical Trials Singapore Study—An Asian Tertiary Cancer Center Experience. <i>JCO Precision Oncology</i> , 2021, 5, 859-875.	3.0	4
40	Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage. <i>Clinical Cancer Research</i> , 2022, 28, 13-22.	7.0	4
41	The role of immunotherapy in fusion-driven lung cancer. <i>Expert Review of Anticancer Therapy</i> , 2021, 21, 461-464.	2.4	3
42	Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib. <i>Lung Cancer: Targets and Therapy</i> , 2021, Volume 12, 11-20.	2.7	2
43	Comparative efficacy of treatments for brain metastases from non-small-cell lung cancer without an EGFR-mutation/ALK-rearrangement: a systematic review and network meta-analysis. <i>World Neurosurgery</i> , 2021, 158, e87-e87.	1.3	2
44	Efficacy of targeted therapies for oncogene-driven lung cancer in early single-arm versus late phase randomized clinical trials: A comparative analysis. <i>Cancer Treatment Reviews</i> , 2022, 104, 102354.	7.7	2
45	The Role of Liquid Biopsy in the Diagnostic Testing Algorithm for Advanced Lung Cancer. <i>Onco</i> , 2022, 2, 181-185.	0.6	2
46	Improving Precision and Implementation of Immuno-Oncology Biomarkers. <i>Journal of Thoracic Oncology</i> , 2021, 16, e91-e93.	1.1	0
47	Characteristics and outcomes of oncology patients requiring admission to an Australian intensive care unit.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21653-e21653.	1.6	0
48	Tumor-Agnostic Biomarkers: Heed Caution, and Why Cell of Origin Still Matters. <i>Onco</i> , 2021, 1, 95-100.	0.6	0
49	Trials without borders — decentralized trials and ensuring access to novel cancer therapies during a global pandemic. <i>ESMO Open</i> , 2022, , 100537.	4.5	0